Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
This move is prompting investors to revisit whether the company's cancer pipeline justifies the new optimism. See our latest analysis for Relay Therapeutics. That surge fits into a broader turnaround, with a roughly 28% 1 month share price return and around 87% year to date share price return, even though the 3 year total shareholder return remains deeply negative. This suggests sentiment is improving, but the long term story is still rebuilding. If Relay's recent move has you rethinking your biotech exposure, it could be worth scanning other potential opportunities across healthcare stocks to see what else is gaining traction. But after such a rapid rebound, are investors still getting in ahead of Relay Therapeutics' potential, or has the market already priced in its ambitious precision oncology pipeline and future growth prospects? Relay Therapeutics currently trades on a price to book ratio of 2.3 times, which looks modest relative to many biotech peers at the latest clos
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025GlobeNewswire
- Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.MarketBeat
- Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 11/6/25 - Miss
RLAY
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- RLAY's page on the SEC website